INM News & Events

InMed Pharmaceuticals provides a pharmaceutical development outlook for 2026. 2026 Development Priorities for INM-901 include: Conduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3/2026. Continue to execute on IND-enabling pharmacology and toxicology studies. Continued development and scale up of drug substance and product manufacturing activities to support IND enabling studies and submission. Engage regulatory / clinical experts to map out topline clinical design for first in human clinical trials for the INM-901. Subject to regulatory feedback and completion of IND-enabling activities, the Company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027. INM-089 Program Outlook - Scientific and development progress and plans include: Generation of data supporting continued evaluation of therapeutic potential. Completion of preclinical studies, including dose-ranging assessment, demonstrating dose proportionality and pharmacologically relevant concentration following dosing. Drug substance and drug product process in place to support IND enabling studies, with further optimization expected in advance of IND submission. Planning for a pre-IND meeting with the FDA in Q4 2026.

InMed Pharmaceuticals announced the "successful" completion of pharmacokinetic studies in large animal models for its Alzheimer's disease candidate INM-901. "This marks the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program," the company stated.

Reports FY25 revenue $4.9M vs $4.6M last year. The Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026. Eric Adams, InMed Chief Executive Officer, commented, "Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901's potential as a small-molecule drug candidate that addresses Alzheimer's disease across several interrelated biological pathways rather than relying on a single mechanism. We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer's pathology and may operate independently of amyloid or tau. These results, alongside favorable behavioral outcomes in long-term preclinical studies, strengthen our conviction that a multi-pathway therapy like INM-901 can contribute meaningfully to disease modification."

InMed Pharmaceuticals announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares or pre-funded warrants in lieu thereof and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share or pre-funded warrant in lieu thereof and associated short-term preferred investment option in a private placement priced at-the-market under Nasdaq rules. The short-term preferred investment option to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the resale registration statement. H.C. Wainwright is acting as the exclusive placement agent for the offering.